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Prevention of spontaneous tumours in female rats by fadrozole
hydrochloride, an aromatase inhibitor
DE Gunson, RE Steele and RY Chau
Division ofPreclinical Safety and Research Departnent, Pharmaceutical Division, Ciba-Geigy Corporation, 556 Morris Ave.,
Suwmmit, New Jersey 07901, USA.
Mammary tumours are oestrge deependent in female Sprague-Dawley rats and in a significant
proportion of women, so pharmacolical treatment to inhibit oestrogen produton is a valuabe therapeutic
masure to prevent or slow the pro on of diseas. Here we show that a non-steoidal aronatase inhibtor,
which competitively inhibits the conversion of enedione to oestone, prevents the development of both
benign and malignant spontaneus mammary neoplasns in female Sprague-Dawley rats. It also slows the
spontaneous development of ptuitary pars dta mas in female rats, and reduces the of
spontaneous hcu ar tumours in male and female rats.
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Every year there are 110 000 new cases of breast cancer in
the USA, and approximately one-half of these are clasifed
as hormone dependent because of the presence of oestrogen
and/or progesterone receptors (Alkegra et al., 1980; O'Neal
Johnston and Metcalf, 1984; Banting et al., 1989). With-
drawal of oestrogen, or treatment with anti-oestogens, leads
to tumour ren in the majority of patients with
hormone-responsive neoplasms (Banting et al., 1989). Fadro-
zole hydrochlonde inhibited oestrogen production in ntro at
concetrations less than 1:1000, 1:1000 and 3:100, the con-
centrations required to produce siilar reductions in pro-
gesterone, corcosterone and aldosterone respectively (Bhat-
nagar et al., 1990), and is devoid of androgenic and oest-
rogenic activity (Steele et al., 1987). It was designed for use
in the treatment of human breast cancer, and has shown
activity against advanced breast cancer in women (Raats et
al., 1992) with minimal effects on aldosterone (Demers et al.,
1990) and glucocorticoid secretion at daily doses
(1-2 mgday ') producing near-maximal suppression of oest-
rogens (Santen et al., 1989). At higher doses (8 mgday-')
fadrozole inhibits basal aldosterone sretion (Demers et al.,
1990) and at 16 mgday- ' bhlts the plasma corisol response
to ACTH but does not alter basal urinary cortisol secretion
(Santen et al., 1989).
Currently an oestrogen receptor antagonist, tamoxifen, is
the most commonly used pharmacological treatment in
women with hormone-dependent breast cancer (Banting et
al., 1989). Such drugs are usually tested in rats with
chemically induced mammary tumours; these are generally
both oestrogen and prolactin dependent in female rats
(Rogers, 1983). Removal of the oestrogen source causes
regression of existing tumours and prevets the occurrence of
further mammany tumours (Rogers, 1983). The oestrogen
source may be removed surgically by ovariectomy (Rogers,
1983), or pharmacologically by an aromatase inhibitor that
prevents the conversion of aromatisable androgens to oestro-
gens (Steele et al., 1987; Schieweck et al., 1988). Fadrozole
hydrochloride, 4-(5,6,7,8-tetrahydrimidazo [1,5-alpyridin-5-yl)
benzonitrile monohydrochloride (CGS 16949A), is a potent
and selective non-steroidal inhibitor of aromatase.
Fadrozole hydrochloride has already been shown to cause
regression of mammary tumours induced by 7,12-dimethyl-
benz(a)anthracene (DMBA) in intact female Sprague-Dawley
rats, with a corresponding reduction in oestradiol levels to
two-thirds those of controls (Schieweck et al., 1988). Almost
complete regreion of palpable tumours and suppon of
the appearance of new tumours was achieved with daily oral
doses of 1.0-8.0 mg kg-' for 6 weeks. Continuous treatment
with 2.0 mg kg-' day-' for 27 weeks caused complete regres-
sion of tumours, supp d the appearance of new tumours
and snificantly prolonged the survival time of tumour-
bearing rats. Here we show that in a 2 year study designed to
assess the carcinogenicity ofthe compound (Huff et al., 1991)
fadrozole hydrochloride completely prevented the appearance
of spontaneous mammary neoplasms in Sprague-Dawley
rats. In addition, it resulted in a dose-related reduction in the
incience of pituitary and hepatic neoplasms.
Materal ad iethods
Female Sprague-Dawley rats from Charles River
Laboratories (Kingston, NY, USA) were housed individually
in suspended, wire-bottomed, metal cages in animal quarters
with controlled temperature (20-2YC), humidity (30-70%)
and lighting (12 h darknss/12 h light). After a 3 week acc-
imation period, when the rats weighed approximately 170 g,
daily dosing with fadrozole hydrochloride (CGS 16949A) in
purified water (USP) by gavage was begun and continued for
2 years. There were 60 rats in each of four groups given 0,
0.05, 0.25 or 1.25 mg kg' day-'. Control rats 1reived only
-f water. Cinical signs were recorded weekly and the
animals were examine for palpable masses every 4 weeks for
the first 9 months, then every 2 weeks for the remainder of
the study. Complete npses were done on all rats either
when they died or were killed moribund, or at the end of 2
years, and body tissues were fixed in 10% neutral buffered
formali subjected to routine histolgical processng, stained
with haemaoxylin and eosin and examin mroopically.
Statiscal analyses usng a time-adjusted trend test were done
on all neopastic lesions (Mantel, 1963; Peto, 1974; Dinse,
1985).
Resds
Fadrozole hydrochloride had no adverse effect on the sur-
vival of treated female rats, and there were very few palpable
masses in treated females. The total number of rats with any
benign and/or malignant neoplasms is shown in Table I.
There were no increases in the incidence of any tumour type,
rather there was a dose-related reduction in the inc e of
malignant neoplasm in treated femals, cay of mam-
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Table I Effect of fadrozole hydrochloride on the incidence of total
neoplasms from all tissues in female rats
Dose (mgkg-' day-') 0 0.05 0.25 1.25
Number of rats 60 60 60 60
With benign neoplasms 55 57 51 47
With malignant neoplasms 27 18 7 5
Total with neoplasms 58 60 52 48
mary tumours (Table II). Females treated with 1.25 mg kg-'
day-' had no mammary tumours at all, whereas 50% of
control rats had either benign or malignant mammary
tumours or both. Females treated with 0.25 mg kg-' day-'
had no malignant mammary tumours and only 11% had
benign mammary tumours. At 0.05 mg kg-' day-', 8% had
malignant mammary tumours and there were fewer benign
mammary tumours than in controls. The reduced mammary
tumour incidence in fadrozole hydrochloride treated female
rats was highly significant (P = 0.0001). Treated females had
pronounced dose-related increases in both food consumption
and body weight (Figure 1). There was no treatment-related
decrease in total mammary tumours of male rats concur-
rently treated with the same doses of fadrozole hydro-
chloride. The number with mammary tumours was 4/58,
2/59, 1/60 and 4/58 in male rats treated with 0, 0.05, 0.25 and
1.25 mg kg-' day-' respectively.
In female rats treated with 0.25 or 1.25mgkg-' day-'
there was a significantly lower incidence (P = 0.012) of
tumours, adenoma or carcinoma, of the pars distalis of the
pituitary (Table II). At these same doses there was an in-
creased incidence of focal hyperplasia of the pars distalis of
the pituitary. Treated females had a significantly lower
incidence (P = 0.019) of liver tumours (hepatocellular
adenomas and carcinomas) than controls (Table II). Male
rats treated with fadrozole hydrochloride also had
significantly fewer (P = 0.013) hepatocellular tumours (10/60,
8/60, 5/60 and 4/60 in rats treated with 0, 0.05, 0.25 and
1.25 mg kg', day-' respectively).
Fadrozole hydrochloride treatment increased the incidence
of several non-neoplastic lesions in female rats (Table HII).
Ovarian stromal hyperplasia was present in females at all
doses. Ovarian hyalinisation, uterine atrophy, pyelonephritis,
and cystitis (inflammation, epithelial hyperplasia and
haemorrhage) were increased at 0.25 and 1.25 mg kg- day- '.
Grossly visible urinary calculi were present in six rats treated
with 0.25 or 1.25mgkg-' day-' fadrozole hydrochloride.
Table I Incidence of benign and malignant mammary, pituitary
and liver neoplasms and pituitary hyperplasia in female rats receiving
fadrozole hydrochloride
Dose (mgkg-' dav'` 0 0.05 0.25 1.25
Nwnber of rats examined 60 60 60 60
Mammary adenomas (B) 4 3 3 0
Mammary fibroadenoma (B) 22 14 5 0
Mammary adenocarcinoma (M) 12 5 0 0
Mammary carcinosarcoma (M) 1 0 0 0
Total mammary tumours 29 20 7 0
Pituitary carcinoma (M) 5 4 0 0
Pituitary adenoma (B) 49 53 45 44
Pituitary focal hyperplasia 3 3 7 8
Hepatocellular adenoma (B) 3 4 0 0
Hepatocellular carcinoma (M) 1 0 0 1
Total hepatocellular tumours 4 4 0 1
B, benign; M, malignant.
Table HI Non-neoplastic compound-related changes in female rats
include enlarged and/or firm ovaries and urinary bladder calculi that
are observable grossly, as well as microscopically detectable lesions
such as ovarian stromal hyperplasia, uterine atrophy and
pyelonephritis
Dose (mgkg-' day') 0 0.05 0.25 1.25
Number per group 60 60 60 60
Ovaries
Enlarged (gross) 0 1 7 10
Firm (gross) 0 0 1 6
Stromal hyperplasia 2 43 53 58
Hyalinisation 0 0 7 27
Uterus
Atrophy 1 2 5 32
Kidneys
Pyelonephritis 1 2 7 11
Urinary bladder
Haemorrhage 0 0 0 4
Epithelial hyperplasia 0 0 4 8
Inflammation (cystitis) 0 0 3 7
Calculi (gross) 0 0 2 4
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There was no increase in the incidence of any tumour type
following daily administration of fadrozole hydrochloride for
2 years to sexually mature male and female Sprague-Dawley
rats. Furthermore, and as anticipated from its mode of
action as an aromatase inhibitor (Steele et al., 1987), fadro-
zole hydrochloride significantly lowers the incidence of spon-
taneous mammary tumours in female rats. Such tumours are
oestrogen dependent (Rogers, 1983), and fadrozole hydro-
chloride has been found to effectively reduce serum oestradiol
in rats with DMBA-induced mammary tumours (Schieweck
et al., 1988; Houjou et al., 1993).
The treated female rats exhibited pronounced dose-related
increases in both food consumption and body weight, so the
reduced incidence of tumours is not related to a reduced
caloric intake, which has been demonstrated to reduce the
incidence of tumours in rats (Keenan et al., 1992). The
increased body weights of the fadrozole treated rats are
attributable to oestrogen deprivation induced by fadrozole
hydrochloride rather than to a direct effect of the compound.
Houjou et al. (1993) noted that the increase in body weight
in female rats following oophorectomy was not further in-
creased by fadrozole hydrochloride.
Schieweck et al. (1988) and Houjou et al. (1993) report
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Fugwe 1 Body weight curves show increases in treated female
rats. Rats were weghed weekly for the first 13 weeks, then every
2 weeks for the next 12 weeks, then every 4 weeks until the end
of the study. Body weight gain was significantly increased
(P = 0.05 at 0.05 mg kg-' day-'), P = 0.01 at 0.25 and
1.25 mg kg-' day-') from the end of the first week. 0, Control;
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that fadrozole hydrochloride causes repression and sup
sion ofthe appearance ofnew tumours in female rats bearing
DMBA-induced mammary tumours in a dose-dependent
manner. A dose of 0.05mg kg` day-' fadrozole hydro-
chloride did not significantly affect DMBA-induced mam-
mary tumours as assessed by measuring tumour volume;
however, a dose of 0.1 mg kg-' day-' had a signiicant but
submaximal effect, and doses of 0.5 mg kg ' day-' or greater
exerted mimal reductions in tumour volume (Schiewek et
al., 1988). Although hormone levels were not measured in
this study, previous studies using rats bearing DMBA-
induced mammary tumours have demonstrated dose-re-
spons reductions in tumour volumes which correlate with
reductions in serum oestradiol (Hojo and Wada, 1991; Hou-
jou et al., 1993). Doses of fadrozole hydrochloride having
submaximal effects on regression of tumour volume also had
submaximal effects on suppression of serm oestradiol.
Doses of 1 mgkg-' day-' or greater maximally suppressed
both tumour growth and serum oestradiol. The decreases in
serum oestradiol are accompanied by increases in serum
androgens (Hojo and Wada, 1991; lino et al., 1991), but
these increases are modest and insufficient to prevent the
increase in serum gonadotrophins that results from the
decrease in circulating oestradiol (Hojo and Wada, 1991;
Houjou et al., 1993).
The incidence of spontaneous mammary tumours in male
rats is markedly lower than in females, and the lack of an
effect of fadrozole hydrochloride on their incidence may
sugget that they are not oestrogen dependent Although
rare, mammary tumours in human males are associated with
oestrogen-related disorders and have been found to be
associated with a high incidence ofoestrogen receptor expres-
sion (Bezwoda et al., 1987; Fox et al., 1992).
The incidence ofpituitary adenomas and carcinomas in the
female rats treated with 0.25 or 1.25mgkg-1 day-' is not
only lower than that in the controls in this study, but also
well below the lowest incidence in our historical data on
female rats (McMartin et al., 1992). While we are not aware
of reports documenting oestrogen deprivation as a means of
reducing the incidence of, or promoting the regression of,
spontaneous adenomas and carcinomas ofthe pars distalis of
the pituitary in rats, the reduced inidence in female rats
treated with fadrozole hydrochloride is conistent with the
observation that pituitary pars distalis adenomas can be
induced in rats by oestrogen treatment (Osamura, 1983). The
oestrogen-induced tumours resemble the naturaly occurring
tumours in that they also produce prolactin (Osamura, 1983).
Prolactin production by pituitary tumours in control rats and
those on lower doses offadrozole hydrochloride may also be
a stimulating factor in mammary tumour development
(Rogers, 1983). Fadrozole hydrochloride completely supp-
resses serum prolactin in rats at doses 1.0mgkg-' day-' or
greater, but suppression is incomplete at lower doses (Houjou
et al., 1993). The higher incidence offocal hyperplasia of the
pars disalis in rats treated with the highest dose offadrozole
hydrochloride most likely reflects a delay in the progression
from focal hyperplasia to adenoma, a common age-related
proliferative lesion of female Sprague-Dawley rats
The lower incidence of liver tumours in male and female
rats administered fadrozole hydrochloride is in sharp contrast
to findings with tamoxifen, which is currently used to treat
advanced breast cancer in post-menopausal women. Tamox-
ifen, an oestrogen antagonist with weak residual oestrogenic
activity, has been found to elicit hepatocellular neoplasms as
early as 3-6 months after administration to female
Sprague-Dawley rats (Williams et al., 1993). Tamoxifen
exerts both oestrogenic and anti-oestrogenic effects depending
on the species and the tissue. In rats and humans, anti-
oestrogens have been shown to exhibit oestrogen-like effects
on lipid metabolism (Lmener and Jordan, 1990), a
predominantly liver-mediated response. The dichotomy ofthe
arcinogenic response of the liver to fadrozole hydrochloride,
a slctive aromataw inhibitor devoid of oestrogenic activity
(Steele et al., 1987), as compared with tamoxifen, an anti-
oestrogen with weak oestrogenic activity (Lener and Jordan,
1990), may be related to expression of oestrogenic activity in
the liver ofthe rat by tamoxifen. It will be ofinterest to see if
other steroidal and non-steroidal aromatase inhibitors also
reduce the incidence of liver tumours in rats.
The incdence of several non-neoplastic, proliferative
lesions was increased in female rats adnmistered fadrozole
hydrochloride. These increases are consistent with the phar-
macological action ofthe compound, i.e. inhibition ofoestro-
gen formation. Ovarian stromal hyperplasia and hyalinisa-
tion were anticipated to result from interference with
negative feedback by oestrogen to the pituitary, resulting in
high levels of gonadotrophic hormones (Ganong, 1987).
These stimulate the ovarian stroma, resulting in dense sindk
cell prolferation, presumably granulosa cells. Trichrome
staining (Luna, 1968) of ovaries with hyalinisation revealed
that this material stains the same as collagen. Presumably,
hyalinisation of the stroma, with extensive areas of acellular
eosinophilic material, occurs in long-standing stromal
hyperplasia and represents excessive collagen deposition.
Although there was a marked increase in ovarian weights
and in the incidence of enlarged, firm ovaries in treated rats,
there was no increase in the incidence of ovarian tumours in
treated rats.
The increased incidence of ascending urinary tract infec-
tions (pyelonephritis and cystitis) is presumably secondary to
the lack of oestrogen, which leads to genitourinary atrophy
and a rise in vaginal pH, in turn resulting in an inreased
susceptibility to the colonisation of the tract by bacteria
(London and Hammond, 1987). Large numbers of oestrogen
receptors are present in the vagina, vulva, urethra and
trigone of the bladduer (London and Hammond, 1987).
In conclusion, fadrozole hydrochloride is highly effective in
reducing the incidence of spontaneous mammary tumours in
rats, and represents the first therapeutic agent to have an
inhibitory effect on spontaneous mammary tumours in rats.
Inhibition of spontaneous mouse mammary tumours by
tamoxifen has been reported (Jordan et al., 1991). However,
mouse mammary tumours are ofviral ongin and may be less
relevant to the human disease. In addition, fadrozole hydro-
chloride also reduced the incidenc of spontaneous pituitary
and hepatic tumours in rats, which may also represent
oestoge-dependent malignancies.
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